Implementation of early and effective treatment for high-risk COVID-19 patients in the outpatient setting is an important public health tool to prevent healthcare systems from reaching a breaking point by enhancing early recovery and reducing hospitalizations. In early clinical trials, two neutralizing monoclonal antibody (nMAb) treatments, bamlanivimab and casirivimab/imdevimab, significantly reduced viral load, symptoms, and hospitalizations, leading the U.S. Food and Drug Administration to issue Emergency Use Authorizations for these agents in high-risk COVID-19 outpatients. Unfortunately, only a small fraction (<5%) of eligible outpatients are currently accessing nMAb treatment due to a number of logistical barriers and clinicians who are not aware or convinced of its therapeutic benefit. The medical and public health communities desperately need scalable solutions for rapid and equitable use of outpatient nMAbs, while simultaneously providing real- world confirmatory evidence of their effectiveness. The State of Colorado implemented a statewide random allocation system for nMAb allocation to eligible patients, the only state with such a system. Building on robust dissemination to enhance uptake of nMAb treatment, this random allocation system will facilitate rapid evaluation of real-world effectiveness of these novel treatments on clinically important, patient-centered outcomes, through a time-sensitive natural experiment. This project uses a type 2 hybrid implementation- effectiveness design to achieve the following specific aims: 1) Assess barriers and facilitators to use of nMAbs statewide, based on diffusion of innovations theory; 2) Develop, implement, and evaluate statewide strategies to optimize equitable nMAb access; and 3) Determine the real-world effectiveness and safety of nMAb treatment in high-risk COVID-19 outpatients. The approach will combine cutting-edge dissemination and implementation methods with a unique natural experiment leveraging the state random allocation system, along with with electronic health record, patient survey, and administrative claims data. This CTSA Administrative Supplement will provide urgently needed real-world T4 translational evidence for nMAb treatment and inform rapid dissemination of current and future outpatient COVID-19 therapies. The deliverables will advance `designing for dissemination' concepts; address pressing concerns to help patients and clinicians manage issues of uncertainty, risk, and urgency; and create a model for rapidly generating high quality real-world evidence in infectious disease pandemics and other future public health emergencies.

Public Health Relevance

As COVID-19 cases, hospitalizations, and deaths strain U.S. health care, there is an urgent need to develop, implement, disseminate, and iteratively evaluate effective therapies to reduce COVID-19 morbidity and mortality. Two novel neutralizing monoclonal antibodies have demonstrated high potential to reduce hospitalizations in high-risk outpatients, but uptake has been low and questions still remain about their effectiveness. In the current project, we will provide urgently needed real-world evidence on neutralizing monoclonal antibody treatments and inform rapid and effective dissemination of current and future outpatient COVID-19 therapies.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
3UL1TR002535-03S3
Application #
10342493
Study Section
Program Officer
Cure, Pablo
Project Start
2018-05-01
Project End
2022-04-30
Budget Start
2021-03-15
Budget End
2021-04-30
Support Year
3
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Pediatrics
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Libby, Anne M; Ingbar, David H; Nearing, Kathryn A et al. (2018) Developing senior leadership for clinical and translational science. J Clin Transl Sci 2:124-128
Cree-Green, Melanie; Xie, Danielle; Rahat, Haseeb et al. (2018) Oral Glucose Tolerance Test Glucose Peak Time Is Most Predictive of Prediabetes and Hepatic Steatosis in Obese Girls. J Endocr Soc 2:547-562
Simon, Stacey L; Vigers, Tim; Campbell, Kristen et al. (2018) Reduced insulin sensitivity is correlated with impaired sleep in adolescents with cystic fibrosis. Pediatr Diabetes 19:1183-1190
Monte, Andrew A; West, Kelsey; McDaniel, Kyle T et al. (2018) CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction. Clin Pharmacol Ther 104:933-939
Neff, Hadlai A; Kellar-Guenther, Yvonne; Jankowski, Catherine M et al. (2018) Turning disability into ability: barriers and facilitators to initiating and maintaining exercise among older men living with HIV. AIDS Care :1-5
Bacon, Emily; Budney, Gregory; Bondy, Jessica et al. (2018) Developing a Regional Distributed Data Network for Surveillance of Chronic Health Conditions: The Colorado Health Observation Regional Data Service. J Public Health Manag Pract :
RISE Consortium (2018) Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care 41:1696-1706
Christiansen, Cory L; Miller, Matthew J; Murray, Amanda M et al. (2018) Behavior-Change Intervention Targeting Physical Function, Walking, and Disability After Dysvascular Amputation: A Randomized Controlled Pilot Trial. Arch Phys Med Rehabil 99:2160-2167
Depner, Christopher M; Melanson, Edward L; McHill, Andrew W et al. (2018) Mistimed food intake and sleep alters 24-hour time-of-day patterns of the human plasma proteome. Proc Natl Acad Sci U S A 115:E5390-E5399
Holden, Samantha K; Medina, Luis D; Hoyt, Brian et al. (2018) Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. Mov Disord 33:1760-1768

Showing the most recent 10 out of 49 publications